Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre Goy

Showing results (81-90 of 164) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|July 5, 2007
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphomaNam H Dang, Luis Fayad, Peter McLaughlin, et al.
American Journal of Hematology|July 13, 2017
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphomaThomas E Witzig, Pier Luigi Zinzani, Thomas M Habermann, et al.
Cancer Research Communications|March 16, 2023
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory LymphomaKristie A Blum, Jeffrey G Supko, Michael B Maris, et al.
British Journal of Haematology|April 25, 2015
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysisChristina Howlett, Sonya J Snedecor, Daniel J Landsburg, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|March 1, 2003
MUC-1 mucin protein expression in B-cell lymphomasJulie Teruya-Feldstein, Gerard B Donnelly, Andre Goy, et al.
Cancer|December 20, 2011
Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVADAnthony R Mato, Jakub Svoboda, Tatyana Feldman, et al.
British Journal of Haematology|August 26, 2010
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphomaJorge E Romaguera, Luis E Fayad, Peter McLaughlin, et al.
Breast (Edinburgh, Scotland)|April 16, 2018
Prolactin Induced Protein (PIP) is a potential biomarker for early stage and malignant breast cancerAnju Gangadharan, Themba Nyirenda, Kishan Patel, et al.
Haematologica|September 8, 2018
ABVD plus rituximab <i>versus</i> ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 studyPaolo Strati, Michelle A Fanale, Yasuhiro Oki, et al.
The American Journal of Pathology|October 15, 2022
Differential Diagnosis of Hematologic and Solid Tumors Using Targeted Transcriptome and Artificial IntelligenceHong Zhang, Muhammad A Qureshi, Mohsin Wahid, et al.
Pageof 17

Showing results (81-90 of 164) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|July 5, 2007
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphomaNam H Dang, Luis Fayad, Peter McLaughlin, et al.
American Journal of Hematology|July 13, 2017
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphomaThomas E Witzig, Pier Luigi Zinzani, Thomas M Habermann, et al.
Cancer Research Communications|March 16, 2023
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory LymphomaKristie A Blum, Jeffrey G Supko, Michael B Maris, et al.
British Journal of Haematology|April 25, 2015
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysisChristina Howlett, Sonya J Snedecor, Daniel J Landsburg, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|March 1, 2003
MUC-1 mucin protein expression in B-cell lymphomasJulie Teruya-Feldstein, Gerard B Donnelly, Andre Goy, et al.
Cancer|December 20, 2011
Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVADAnthony R Mato, Jakub Svoboda, Tatyana Feldman, et al.
British Journal of Haematology|August 26, 2010
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphomaJorge E Romaguera, Luis E Fayad, Peter McLaughlin, et al.
Breast (Edinburgh, Scotland)|April 16, 2018
Prolactin Induced Protein (PIP) is a potential biomarker for early stage and malignant breast cancerAnju Gangadharan, Themba Nyirenda, Kishan Patel, et al.
Haematologica|September 8, 2018
ABVD plus rituximab <i>versus</i> ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 studyPaolo Strati, Michelle A Fanale, Yasuhiro Oki, et al.
The American Journal of Pathology|October 15, 2022
Differential Diagnosis of Hematologic and Solid Tumors Using Targeted Transcriptome and Artificial IntelligenceHong Zhang, Muhammad A Qureshi, Mohsin Wahid, et al.
Pageof 17